Company news

Humanwell Healthcare (group) Co.,ltd. Class A (SSE:600079) news

Humanwell Healthcare (group) Co.,ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: (600079)"Humanwell Healthcare (Group) Co., Ltd."Indicative…

Humanwell Healthcare (group) Co.,ltd. Class A (SSE:600079) news

Press releases & updates

(600079)"Humanwell Healthcare (Group) Co., Ltd."Indicative Announcement on Disclosure of Proposal for 2026 Private Placement of A-Shares (Second Revised Draft)

(600079)"Humanwell Healthcare (Group) Co., Ltd."Announcement on the Dilution of Immediate Returns, Measures to Mitigate Such Dilution and the Undertakings by Relevant Parties in Relation to the Private Placement of A-Shares (Second Revised Draft)

(600079)"Humanwell Healthcare (Group) Co., Ltd."Announcement on Signing Supplemental Agreement (II) to the Conditional Share Subscription Agreement for the Private Placement of Shares with the Controlling Shareholder and Related Party Transaction

(600079)"Humanwell Healthcare (Group) Co., Ltd."Announcement on Resolutions of the 12th Meeting of the 11th Board of Directors

(600079)"Humanwell Healthcare (Group) Co., Ltd."Announcement on Adjustments to the Plan for Private Placement of Shares

"Humanwell Healthcare (Group) Co., Ltd."Announcement on Explanation of Revisions to Proposal for 2026 Private Placement of A-Shares (Second Revised Draft) and Relevant Documents

"Humanwell Healthcare (Group) Co., Ltd."Indicative Announcement on the Reply to the Review Inquiry Letter Regarding the Application Documents for the Private Placement of Shares and Updates of the Prospectus and Other Application Documents

"Humanwell Healthcare (Group) Co., Ltd."Announcement on Obtaining Drug Registration Certificate for Phloroglucinol Orally Disintegrating Tablets

"Humanwell Healthcare (Group) Co., Ltd."Announcement on Completion of the Sale of Assets by a Wholly-owned Subsidiary

"Humanwell Healthcare (Group) Co., Ltd."Announcement on the Initiation of Phase II Clinical Trials for RFUS-949 Tablet

"Humanwell Healthcare (Group) Co., Ltd."Indicative Announcement on Acceptance of Application of the Subsidiary for Drug Marketing Authorization

"Humanwell Healthcare (Group) Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing

"Humanwell Healthcare (Group) Co., Ltd."Announcement on Resolutions of the 11th Meeting of the 11th Board of Directors

"Humanwell Healthcare (Group) Co., Ltd."Announcement on the Initiation of Phase II Clinical Trials for RFUS-188 Injection

"Humanwell Healthcare (Group) Co., Ltd."Announcement on Obtaining the Notice of Approval for Clinical Trial of Sufentanil Citrate Injection

"Humanwell Healthcare (Group) Co., Ltd."Announcement on Obtaining the Drug Registration Certificate for Brexpiprazole Tablets

"Humanwell Healthcare (Group) Co., Ltd."Announcement on Acceptance by Shanghai Stock Exchange of Application for Private Placement of A Shares

"Humanwell Healthcare (Group) Co., Ltd."Announcement on the Progress of Asset Disposal by Wholly-Owned Subsidiary

"Humanwell Healthcare (Group) Co., Ltd."Announcement on Acquisition of the Drug Registration Certificate for Carbamazepine Sustained-Release Tablets (II)

"Humanwell Healthcare (Group) Co., Ltd."Announcement on Obtaining the Drug Registration Certificate for Vinorelbine Tartrate Soft Capsules

"Humanwell Healthcare (Group) Co., Ltd."Announcement on the Approval of Nintedanib Soft Capsules by the US FDA

"Humanwell Healthcare (Group) Co., Ltd."Announcement on the Initiation of Phase II Clinical Trial for HW211026 Ointment

"Humanwell Healthcare (Group) Co., Ltd."Announcement on Obtaining Notice of Approval for Drug Clinical Trial for Hydromorphone Hydrochloride Tablets

"Humanwell Healthcare (Group) Co., Ltd."Announcement on Attending the 2026 Collective Reception Day for Investors of Listed Companies in Hubei Jurisdiction and 2025 Annual Performance Briefing

Announcement on Obtaining Notice of Approval for Drug Clinical Trial of HWS113 for Injection

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026

Announcement on Tapentadol Hydrochloride Oral Solution Obtaining Notice of Approval for Drug Clinical Trial

Indicative Announcement on Disclosure of the Plan for Issuing A-shares to Specific Objects in 2026 (Revised Draft)

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on Resolutions of the 9th Meeting of the 11th Board of Directors

Indicative Announcement on Acceptance of Application for Drug Marketing Authorization of Subsidiary

Announcement on Hydrochloride R-Chloroamphetamine Injection Obtaining Notice of Approval for Drug Clinical Trial

Announcement on RFUS-188 Injection Obtaining Notice of Approval for Drug Clinical Trial

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

Report for Q1 2026

Announcement on Resolutions of the 7th Meeting of the 11th Board of Directors

Announcement on Obtaining Marketing Authorization from the German Federal Institute for Drugs and Medical Devices (BfArM) for Remifentanil Hydrochloride for Injection

Announcement on Convening the 2025 Annual Performance Briefing

Announcement on Obtaining Drug Registration Certificate by Subsidiary

Announcement on Risk Assessment Report for China Merchants Group Finance Co., Ltd.

Announcement on Initiation of Phase II Clinical Trial for HW091077 Tablets

Announcement on Holding Subsidiary's Passing EU GMP Compliance Inspection

Announcement on Micafungin Sodium for Injection Obtaining US FDA Approval

Announcement on the Temporary Suspension of the Shareholders’ Meeting to Deliberate on the Issuance of A-shares to Specific Investors in 2026

Announcement on Progress in the Establishment of Private Equity Fund Investment and Related Party Transaction

Announcement on HW221043 Tablets Obtaining Notice of Approval for Drug Clinical Trials

Announcement on Receiving the Decision for Administrative Penalty from Hubei Securities Regulatory Bureau of China Securities Regulatory Commission

Announcement on Progress in Establishment in Private Equity Fund Investment and Related Party Transaction

Indicative Announcement on the Results of Controlling Shareholder's Share Increase and Equity Change Reaching 1% Scale

Announcement on HW252001 Tablets Obtaining Notice of Approval for Drug Clinical Trials